Data Show Most Clinicians Unclear on Efficacy, Substitution, and Extrapolation of Indications for Biosimilars
Reston, Virginia - September 28, 2018 - Most clinicians are unclear on the efficacy, substitution, and extrapolation of indications of biosimilars, according to new data being presented by Clinical Care Options (CCO) at both the 2018 ASCO Quality Care Symposium and 2018 ACR/ARHP Annual Meeting. However, after participating in targeted continuing medical education, these clinicians better understood biosimilars and were more likely to prescribe them.
In total, 3347 specialists and primary care clinicians participated in CCO’s online educational program, including oncologists, rheumatologists, gastroenterologists, and dermatologists. CCO identified persistent misunderstandings about biosimilars at baseline.
“These uncovered gaps may explain why some clinicians are unwilling to consider biosimilars as a treatment option for their patients,” said Tina B. Stacy, PharmD, BCOP, CHCP, Executive Vice President, Educational Strategy at CCO. “Through this analysis, we have shown that continuing medical education is a viable platform by which to improve clinicians’ competence with biosimilars, potentially removing barriers for consideration of their use.”
The educational program successfully increased clinicians’ understanding of and willingness to prescribe biosimilars, potentially removing barriers to the use of these new and potentially less expensive treatment options for patients.